Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point for the accessibility of weight loss drugs. Since then, Zepbound, the ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.